Finding the Target:In Silicoand Genetic Screening for Mechanistically Novel Drugs in Pulmonary Arterial Hypertension

Hearables, in-ear sensing devices for bio-signal acquisition: a narrative review

INTRODUCTION

Hearables are ear devices used for multiple purposes including ubiquitous/remote monitoring of vital signals. This can support early detection, prevention, and management of urgent/non-urgent healthcare needs. This review therefore seeks to analyse the challenges and capabilities of hearables used to monitor human physiological signals.

AREAS COVERED

Studies were identified via search (Medline, Embase, Web of Science, Cochrane Library, Scopus) and conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Bias assessment used the Mixed Methods Appraisal Tool 2018 and Quality Assessment of Diagnostic Accuracy Studies 2nd Edition. 92/631 studies met the inclusion criteria and were qualitatively analysed. The outcomes, applications, advantages and limitations were discussed according to the vital signal measured. The bias risk ranged from low to high, with most studies facing moderate to high risk in subject selection due to small sample sizes.

EXPERT OPINION

: Most studies reported good outcomes for ear signal acquisition compared to reference devices. To improve practicability and implementation, wireless connectivity, battery life, impact of motion/environmental artifacts and comfort need to be addressed going forward. Hearable technologies have also shown potential synergies with hearing aids. In future, multimodal ear-sensing devices opens the possibility of comprehensive health monitoring within daily life.

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases

Progressive fibrosing interstitial lung diseases (ILDs) involve similar pathophysiological processes, indicating the potential for common approaches to treatment. Nintedanib (Ofev®), an intracellular tyrosine kinase inhibitor (TKI) with antifibrotic properties, was one of the first drugs approved for use in idiopathic pulmonary fibrosis (IPF) and has more recently been approved for use in other chronic fibrosing ILDs with a progressive phenotype and systemic sclerosis-associated ILD (SSc-ILD). In multinational phase III trials, nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) in adults with IPF, other progressive fibrosing ILDs and SSc-ILD. Reductions in FVC decline with nintedanib in patients with IPF and severe gas exchange impairment were comparable to those in patients with milder disease. Real-world experience in patients with IPF supports the effectiveness of nintedanib in slowing ILD progression. Nintedanib had a manageable tolerability profile in patients with fibrotic ILDs in clinical trials and real-world studies. No new safety signals have emerged from global pharmacovigilance data. Nintedanib continues to represent an important therapeutic option in patients with IPF and is the first drug to be approved for use in patients with other chronic fibrosing ILDs with a progressive phenotype or SSc-ILD, with these approvals expanding the range of fibrotic ILDs for which nintedanib can be prescribed.

Instruments for Detecting Moral Distress in Clinical Nurses: A Systematic Review

Moral distress (MD) has become a seriously negative problem experienced by healthcare professionals, especially clinical nurses. Early and accurate detection of MD by the validated and reliable instrument is critically important to further develop an effective intervention strategy. We performed the current systematic review to comprehensively summarize the evidence of instruments for the detection of MD in clinical nurses. The research design was a systematic literature review. We assigned 2 investigators to independently search potential studies in PubMed, EMBASE, and China National Knowledge Infrastructure (CNKI) from their inception to June 2020. We used data extraction table extracting essential information, and the modified critical appraisal tool evaluating the reliability and validity of eligible instruments. Finally, we qualitatively summarized results of all included instruments. No ethical approval was required because this systematic review was performed based on published studies. We included 16 eligible studies covering 10 original and 6 revised or modified instruments for the final analysis. The overall quality of all instruments was moderate because test-retest reliability was inadequately examined in most instruments. Of 16 instruments, MDS-revised (MDS-R) was broadly validated and employed in different working or cultural settings. Meanwhile, it also extensively expands to specifically detect MD. Moreover, other instruments including moral distress risk scale (MDSR) and moral distress thermometer (MDT) should be further validated and utilized because it covered the gap missed by most instruments. Although several instruments have been made available for clinical nurses, some of them have inadequate psychometric properties test, especially test-retest reliability evaluation. Meanwhile, most of them have not be validated and employed in other working or cultural settings. We therefore suggested further studies to validate the psychometric properties of existing instruments and then employed instruments with high reliability and validity to detect MD in clinical nurses.